Glutamate Dehydrogenase 1 Inhibitors and Methods of Treating Cancer

Abstract

This disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof.

1 . A method of treating cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof, wherein the inhibitor is iRNA that targets GLUD1 mRNA. 
     
     
         2 . The method of  claim 1  wherein the inhibitor is shRNA designed to knock down gene expression. 
     
     
         3 . The method of  claim 1 , wherein the inhibitor is a viral vector that encodes shRNA designed to knock down gene expression. 
     
     
         4 . The method of  claim 4  wherein the inhibitor is administered in combination with a second chemotherapeutic agent. 
     
     
         5 . The method of  claim 4 , wherein the second chemotherapeutic agent is gefitinib, erlotinib, docetaxel, cis-platin, 5-fluorouracil, gemcitabine, tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin, vincristine, vinblastine, vindesine, vinorelbine taxol, taxotere, etoposide, teniposide, amsacrine, topotecan, camptothecin bortezomib anegrilide, tamoxifen, toremifene, raloxifene, droloxifene, iodoxyfene fulvestrant, bicalutamide, flutamide, nilutamide, cyproterone, goserelin, leuprorelin, buserelin, megestrol anastrozole, letrozole, vorazole, exemestane, finasteride, marimastat, trastuzumab, cetuximab, dasatinib, imatinib, bevacizumab, combretastatin, thalidomide, and/or lenalidomide or combinations thereof. 
     
     
         6 . The method of  claim 1 , wherein the cancer is selected from the group consisting of leukemia, cervical, ovarian, colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate, head, neck, and renal cancer.